2025年4月7日 星期一
首页        期刊介绍        编委会        投稿指南        期刊订阅        广告合作        联系我们        English
河北医学  2018, Vol. 24 Issue (11): 1857-1861    DOI: 10.3969/j.issn.1006-6233.2018.11.024
  论著 本期目录 | 过刊浏览 | 高级检索 |
替加环素分别联合血必净与头孢哌酮舒巴坦治疗耐碳青霉烯泛耐药鲍曼不动杆菌感染的疗效及安全性比较
马新,郑晶晶,张杰,周志安,边树伟,白艳
河北省承德市中医院, 河北 承德 067000
Comparison of Efficacy and Safety of Tegacycline combined with Xuebijing and Cefoperazone Sulbactam in the treatment of Carbapenem-resistant Acinetobacter Baumannii Infection
MA Xin, ZHENG Jingjing, ZHANG Jie, et al
Chengde Hospital of Traditional Chinese Medicine, Hebei Chengde 067000, China
全文: PDF (1288 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要  目的: 探讨替加环素分别联合血必净与头孢哌酮舒巴坦治疗耐碳青霉烯泛耐药鲍曼不动杆菌感染的疗效及安全性。方法: 将2016年2月至2017年2月92例耐碳青霉烯泛耐药鲍曼不动杆菌肺部感染患者按照随机数表法分为研究组(n=46)与对照组(n=46),研究组患者给予替加环素联合血必净治疗,对照组患者给予替加环素联合头孢哌酮舒巴坦治疗,比较两组临床疗效、细菌清除率、炎症反应相关指标[C反应蛋白(CRP)、白细胞计数(WBC)、降钙素原(PCT)]、病情发展情况及不良反应发生情况。结果: 研究组治疗总有效率、细菌清除率分别为91.30%、78.26%,明显高于对照组71.74%、58.70%,差异具有统计学意义(P<0.05);治疗后,研究组CRP、WBC、PCT水平、CPIS评分、APACHE Ⅱ评分均明显低于治疗前与对照组,差异具有统计学意义(P<0.05);研究组不良反应总发生率为6.52%,明显低于对照组21.74%,差异具有统计学意义(P<0.05);治疗后,对照组BUN、Scr水平高于研究组,差异具有统计学意义(P<0.05)。结论: 替加环素分别联合血必净治疗耐碳青霉烯泛耐药鲍曼不动杆菌感染疗效确切,可显著提高细菌清除率,减轻炎症反应,安全性高,较替加环素联合头孢哌酮舒巴坦治疗效果更好。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 鲍曼不动杆菌 替加环素 血必净 头孢哌酮舒巴坦 碳青霉烯    
AbstractObjective: To investigate investigate the efficacy and safety of tigacycline combined with Xuebijing and cefoperazone sulbactam in the treatment of carbapenem-resistant Acinetobacter baumannii infection. Methods: From February 2016 to February 2017, 92 patients with carbapenem-resistant Acinetobacter baumannii pneumonia were randomly divided into study group (n = 46) and control group (n = 46). Patients in the study group were treated with tegacycline combined with Xuebijing, while patients in the control group were treated with tegacycline combined with cefoperazone sulbactam. The clinical efficacy, bacterial clearance rate, inflammatory response related indicators [C-reactive protein (CRP), white blood cell count (WBC), procalcitonin (PCT)], disease development and adverse reactions were compared between the two groups. Results: The total effective rate and bacterial eradication rate in research group were 91.30% and 78.26%, which were higher than 71.74% and 58.70% in control group (P<0.05); After treatment, the CRP, WBC, PCT levels, CPIS and APACHE II scores in research group were lower than those before treatment and control group (P<0.05); The total incidence of adverse reactions in research group was 6.52%, which was lower than 21.74% in control group (P<0.05); After treatment, the levels of BUN and Scr in control group were higher than those in research group (P<0.05). Conclusion: Tigecycline cobined with Xuebijing in treatment of carbapenem-resistant Acinetobacter baumannii is effective. It can increase the bacterial eradication rate, reduce inflammatory response and have high safety, which has better curative effects compared with tigecycline cobined with cefoperazone-sulbactam.
Key wordsAcinetobacter baumanniiTigecycline    Xuebijing    Cefoperazone-sulbactam    Carbapenem
    
基金资助:河北省承德市科学技术研究与发展计划项目,(编号:201601A021)
引用本文:   
马新,郑晶晶,张杰,周志安,边树伟,白艳. 替加环素分别联合血必净与头孢哌酮舒巴坦治疗耐碳青霉烯泛耐药鲍曼不动杆菌感染的疗效及安全性比较[J]. 河北医学, 2018, 24(11): 1857-1861.
MA Xin, ZHENG Jingjing, ZHANG Jie, et al. Comparison of Efficacy and Safety of Tegacycline combined with Xuebijing and Cefoperazone Sulbactam in the treatment of Carbapenem-resistant Acinetobacter Baumannii Infection. HeBei Med, 2018, 24(11): 1857-1861.
链接本文:  
http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2018.11.024     或     http://www.hbyxzzs.cn/CN/Y2018/V24/I11/1857
冀ICP备2025106803号    冀公网安备13080202000786号
版权所有 © 2016 《河北医学》杂志社
本系统由北京玛格泰克科技发展有限公司设计开发